145 related articles for article (PubMed ID: 12804102)
21. Deletion of thyrotropin receptor residue Asp403 in a hyperfunctioning thyroid nodule provides insight into the role of the ectodomain in ligand-induced receptor activation.
Nishihara E; Chen CR; Mizutori-Sasai Y; Ito M; Kubota S; Amino N; Miyauchi A; Rapoport B
J Endocrinol Invest; 2012 Jan; 35(1):49-53. PubMed ID: 21597314
[TBL] [Abstract][Full Text] [Related]
22. Autonomously functioning thyroid nodules in a former iodine-deficient area commonly harbor gain-of-function mutations in the thyrotropin signaling pathway.
Georgopoulos NA; Sykiotis GP; Sgourou A; Papachatzopoulou A; Markou KB; Kyriazopoulou V; Papavassiliou AG; Vagenakis AG
Eur J Endocrinol; 2003 Oct; 149(4):287-92. PubMed ID: 14514342
[TBL] [Abstract][Full Text] [Related]
23. [Activating mutations of the TSH receptor: a synthesis highlighting certain pediatric aspects].
Polak M
Arch Pediatr; 1998; 5 Suppl 4():375S-379S. PubMed ID: 9853087
[TBL] [Abstract][Full Text] [Related]
24. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G
J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356
[TBL] [Abstract][Full Text] [Related]
25. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
26. [TSH receptor double mutation in functional autonomic thyroid nodule].
Semlitsch G; Höfler G; Langsteger W; Lax S; Zatloukal K; Berger A; Eber O
Acta Med Austriaca; 1995; 22(4):75-7. PubMed ID: 8835426
[TBL] [Abstract][Full Text] [Related]
27. New pathophysiological mechanisms for hyperthyroidism.
Vassart G
Horm Res; 1997; 48 Suppl 4():47-50. PubMed ID: 9350447
[TBL] [Abstract][Full Text] [Related]
28. Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene.
Polak M
Arch Med Res; 1999; 30(6):510-3. PubMed ID: 10714365
[TBL] [Abstract][Full Text] [Related]
29. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas.
Persani L; Lania A; Alberti L; Romoli R; Mantovani G; Filetti S; Spada A; Conti M
J Clin Endocrinol Metab; 2000 Aug; 85(8):2872-8. PubMed ID: 10946896
[TBL] [Abstract][Full Text] [Related]
30. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas.
Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E
Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968
[TBL] [Abstract][Full Text] [Related]
31. Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms.
Derwahl M; Manole D; Sobke A; Broecker M
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S6-9. PubMed ID: 9867188
[TBL] [Abstract][Full Text] [Related]
32. Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas.
Derwahl M
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():32-5. PubMed ID: 8980997
[TBL] [Abstract][Full Text] [Related]
33. Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations.
Hébrant A; van Staveren WC; Maenhaut C; Dumont JE; Leclère J
Eur J Endocrinol; 2011 Jan; 164(1):1-9. PubMed ID: 20926595
[TBL] [Abstract][Full Text] [Related]
34. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
35. [Point mutation of thyrotropin receptors as the main cause of autonomously functioning thyroid nodules: experiences in the framework of our Styrian patients].
Lax SF; Semlitsch G; Noiges R; Höfler G
Acta Med Austriaca; 2000; 27(2):49-50. PubMed ID: 10812465
[TBL] [Abstract][Full Text] [Related]
36. Lack of mutations in the TSHr and Gsalpha genes in TSHr antibody negative Graves' disease.
Elgadi A; Frisk T; Larsson C; Wallin G; Höög A; Zedenius J; Norgren S
Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):516-21. PubMed ID: 16235153
[TBL] [Abstract][Full Text] [Related]
37. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution.
Derwahl M
J Clin Endocrinol Metab; 1996 Aug; 81(8):2783-5. PubMed ID: 8768829
[TBL] [Abstract][Full Text] [Related]
38. Mini-invasive videoassisted thyroid lobectomy for neonatal hyperfunctioning adenoma related to a somatic TSHr gene mutation.
Stocco E; Pelizzo MR; Grassetto G; Pagetta C; Larizza D; Massaro A; Marzola MC; Rubello D
Ann Endocrinol (Paris); 2012 Jun; 73(3):230-2. PubMed ID: 22503667
[TBL] [Abstract][Full Text] [Related]
39. High prevalence of TSHR/Gsα mutation-negative clonal hot thyroid nodules (HNs) in a Turkish cohort.
Sancak S; Jaeschke H; Eren F; Tarcin O; Guellueoglu B; Sen LS; Sever Z; Gozu HI; Bircan R; Akalin S; Paschke R; Eszlinger M
Horm Metab Res; 2011 Jul; 43(8):562-8. PubMed ID: 21773967
[TBL] [Abstract][Full Text] [Related]
40. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy.
Porcellini A; Ciullo I; Laviola L; Amabile G; Fenzi G; Avvedimento VE
J Clin Endocrinol Metab; 1994 Aug; 79(2):657-61. PubMed ID: 8045989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
